SVA:CC - Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022
(TheNewswire)
LONDON, ONTARIO – TheNewswire - May 9, 2022 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapytherapeutics company focused on developing a potential ‘functionalcure’ for type 1 diabetes (T1D) and other chronic diseases, ispleased to announce that that an abstract has been selected for an oral podiumpresentation at the upcoming American Diabetes Association (ADA)82 nd Scientific Sessions, to be held from June 3-7, 2022, at the Ernest N.Morial Convention Center in New Orleans, LA.
Abstract 306-OR: Modified Approach for Improved Islet Allotransplantationinto Prevascularized Sernova Cell Pouch TM Device:Preliminary Results of the Phase I/II Clinical Trial at University ofChicago
Abstract Session: Islet Transplantation —Basic Science
Session Date/Time: Monday,June 6, 2022 at 2:15 PM – 4:15 PM CT
Presentation Time: 3:15-3:30PM CT
Authors: Bachul PJ,Perez-Guetierrez A, Ling-jia Wang, Golab K, Basto L, Perea L, TibudanM, Braden J, Thomas C, Philipson L, Barth R, Fung JJ, Witkowski P
Sernova will disclose additional information about the presentation atthe time of the conference in alignment with the American DiabetesAssociation’s abstract embargo policies.
ABOUT SERNOVA
Sernova is developing regenerative medicine cell therapeutic solutionsusing a medical device (Cell Pouch) and immune protected therapeuticcells / tissues (i.e. human donor cells, corrected human cells andstem cell-derived cells) to improve the treatment and quality of lifeof people with chronic metabolic diseases such as insulin-dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through cellular production of proteins or hormones missing orin short supply within the body. For more information, please visitwww.sernova.com.
ABOUT SERNOVA’S CELL POUCH SYSTEMCELL THERAPY PLATFORM
The Cell Pouch, as part of the Cell Pouch System, is a novel,proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. After implantation, the device incorporates withtissue, forming highly vascularized, native tissue chambers for thetransplantation and function of therapeutic cells, that releaseproteins and hormones as required to treat disease.
The Cell Pouch, along with therapeutic cells, has been shown toprovide long-term safety and efficacy in small and large animal modelsof diabetes and has been proven to provide a biologically compatibleenvironment for insulin-producing cells in humans in a Canadianfirst-in-human study. Sernova is currently conducting a Phase 1/2clinical trial study at the University of Chicago. Encouraging interimresults have been presented at several international scientificconferences.
FOR FURTHER INFORMATION, PLEASECONTACT:
Corporate:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Tel: 212-915-2577
Media:
Elizabeth Miller, M.D.
LifeSci Communications
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of thecompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management’s beliefs withrespect to future events and are based on information currentlyavailable to management on the date such statements were made. Manyfactors could cause Sernova’s actual results, performances orachievements to not be as anticipated, estimated or intended or todiffer materially from those expressed or implied by theforward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the company’s quarterly and annual filings availableon www.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2022 TheNewswire - All rights reserved.